基于mRNA的抗SARS-CoV-2疫苗接种后8个月的细胞和体液反应随访
Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines.
作者信息
Gil-Manso Sergio, Carbonell Diego, Pérez-Fernández Verónica Astrid, López-Esteban Rocío, Alonso Roberto, Muñoz Patricia, Ochando Jordi, Sánchez-Arcilla Ignacio, Bellón Jose M, Correa-Rocha Rafael, Pion Marjorie
机构信息
Advanced Immunoregulation Group, Gregorio Marañón Health Research Institute (IiSGM), Gregorio Marañón University General Hospital, 28009 Madrid, Spain.
Department of Hematology, Gregorio Marañón Health Research Institute (IiSGM), Gregorio Marañón University General Hospital, 28009 Madrid, Spain.
出版信息
Biomedicines. 2022 Jul 12;10(7):1676. doi: 10.3390/biomedicines10071676.
Vaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of COVID-19. This work aims to study the evolution of the cellular and humoral responses conferred by two mRNA vaccines after two doses against SARS-CoV-2. On days 30 and 240 after the second dose of both vaccines, the anti-S antibodies in plasma were evaluated from 82 volunteers vaccinated with BNT162b2 and 68 vaccinated with mRNA-1273. Peripheral blood was stimulated with peptides encompassing the entire SARS-CoV-2 Spike sequence. IgG Anti-S antibodies (humoral) were quantified on plasma, and inflammatory cytokines (cellular) were measured after stimulation. We observed a higher response (both humoral and cellular) with the mRNA-1273 vaccine. Stratifying by age and gender, differences between vaccines were observed, especially in women under 48 and men over 48 years old. Therefore, this work could help to set up a vaccination strategy that could be applied to confer maximum immunity.
接种新型冠状病毒 2 型（SARS-CoV-2）疫苗已成为降低 COVID-19 死亡率和严重程度的主要方法。这项工作旨在研究两种 mRNA 疫苗在接种两剂后针对 SARS-CoV-2 所产生的细胞和体液免疫反应的演变。在接种两种疫苗的第二剂后的第 30 天和第 240 天，对 82 名接种 BNT162b2 的志愿者和 68 名接种 mRNA-1273 的志愿者的血浆中的抗 S 抗体进行了评估。用覆盖整个 SARS-CoV-2 刺突序列的肽刺激外周血。对血浆中的 IgG 抗 S 抗体（体液免疫）进行定量，并在刺激后测量炎性细胞因子（细胞免疫）。我们观察到 mRNA-1273 疫苗产生了更高的反应（体液免疫和细胞免疫均如此）。按年龄和性别分层后，观察到了疫苗之间的差异，尤其是在 48 岁以下的女性和 48 岁以上的男性中。因此，这项工作有助于制定一种可用于提供最大免疫力的疫苗接种策略。
Zotero 插件